Laurel A Menapace1, Alok A Khorana. 1. James P. Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA.
Abstract
PURPOSE OF REVIEW: Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in cancer patients. A significant proportion of cancer-associated VTE occurs in the ambulatory setting and is associated with poorer outcomes and reduced survival. Risk for VTE is influenced by patient, cancer and treatment-specific factors. RECENT FINDINGS: Recent studies have identified biomarkers associated with increased VTE risk in malignancy, including leukocyte and platelet counts, tissue factor, prothrombin split products, D-dimer, P-selectin, factor VIII and C-reactive protein. Recent and ongoing clinical trials have focused on VTE prophylaxis with low-molecular weight heparins in high-risk cancer outpatients, particularly those with pancreatic cancer. These studies have yielded encouraging preliminary results but whether thromboprophylaxis provides significant benefit to unselected cancer outpatients remains unclear. SUMMARY: A risk stratification model incorporating known risk factors and biomarkers can identify those patients at highest risk. This review focuses on emerging data regarding risk assessment and benefit of thromboprophylaxis in patients with cancer.
PURPOSE OF REVIEW: Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in cancerpatients. A significant proportion of cancer-associated VTE occurs in the ambulatory setting and is associated with poorer outcomes and reduced survival. Risk for VTE is influenced by patient, cancer and treatment-specific factors. RECENT FINDINGS: Recent studies have identified biomarkers associated with increased VTE risk in malignancy, including leukocyte and platelet counts, tissue factor, prothrombin split products, D-dimer, P-selectin, factor VIII and C-reactive protein. Recent and ongoing clinical trials have focused on VTE prophylaxis with low-molecular weight heparins in high-risk cancer outpatients, particularly those with pancreatic cancer. These studies have yielded encouraging preliminary results but whether thromboprophylaxis provides significant benefit to unselected cancer outpatients remains unclear. SUMMARY: A risk stratification model incorporating known risk factors and biomarkers can identify those patients at highest risk. This review focuses on emerging data regarding risk assessment and benefit of thromboprophylaxis in patients with cancer.
Authors: Charles L Bennett; Cara Angelotta; Paul R Yarnold; Andrew M Evens; Jeffrey A Zonder; Dennis W Raisch; Paul Richardson Journal: JAMA Date: 2006-12-06 Impact factor: 56.272
Authors: Lawrence D Wagman; Melissa F Baird; Charles L Bennett; Paula L Bockenstedt; Spero R Cataland; John Fanikos; Patrick F Fogarty; Samuel Z Goldhaber; Tejpal S Grover; William Haire; Hani Hassoun; Mohammad Jahanzeb; Lawrence L Leung; Michael L Linenberger; Michael M Millenson; Thomas L Ortel; Riad Salem; Judy L Smith; Michael B Streiff Journal: J Natl Compr Canc Netw Date: 2006-10 Impact factor: 11.908
Authors: N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm Journal: Medicine (Baltimore) Date: 1999-09 Impact factor: 1.889
Authors: Alok A Khorana; Charles W Francis; Eva Culakova; Richard I Fisher; Nicole M Kuderer; Gary H Lyman Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz Journal: J Natl Cancer Inst Date: 2007-08-08 Impact factor: 13.506